Validation of a Human In Vitro Vaginal Irritation Test

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 2R44HD050023-02
Agency Tracking Number: HD050023
Amount: $1,205,750.00
Phase: Phase II
Program: SBIR
Awards Year: 2009
Solitcitation Year: 2009
Solitcitation Topic Code: N/A
Solitcitation Number: PHS2009-2
Small Business Information
MATTEK CORPORATION
MATTEK CORPORATION, 200 HOMER AVE, ASHLAND, MA, -
Duns: 147365936
Hubzone Owned: Y
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 SEYOUM AYEHUNIE
 (508) 881-6771
 SAYEHUNIE@MATTEK.COM
Business Contact
 SEYOUM AYEHUNIE
Phone: (508) 881-6771
Email: mklausner@mattek.com
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): During Phase 1 research, the effects of 6 model test materials on a highly differentiated vaginal- ectocervical (VEC) tissue model were studied. Effects on tissue viability, structure, barrier function, and inflammatory cytokine release were monitored. Many of the assays gave results which supported one another and increased confidence in the in vitro results. For instance, histological damage and cytokine release paralleled losses in tissue viability. In addition, decreases in barrier function were measured when tissue viability decreased although the data indicated that barrier function was a more sensitive endpoint (i.e. decreases in barrier function occurred at lower concentrations that did not decrease tissue viability). Importantly, the one material which was mildly irritating in the rabbit vaginal irritation test induced significant decreases in tissue viability and barrier function and increased inflammatory mediator release. In addition, an economic analysis showed the in vitro method to be a cost-effective alternative to the currently used rabbit vaginal irritation test methodology. During Phase 2, the utility of the in vitro assay system will be further expanded to predict vaginal irritation following chronic, repeat exposure. Using the endpoints developed in Phase 1, a prediction model will be developed to accurately assess the in vivo vaginal irritation of test materials and formulations. The method will be transferred to outside contract testing labs and a multi-lab GLP validation study will be performed. In addition, the short and long term reproducibility of the assay will be assessed, and a high throughput version of the assay method will be developed. PUBLIC HEALTH RELEVANCE: A predictive test system for assessing the vaginal irritation potential of chemicals and formulations will have far reaching application in industries involved in women's care products, microbicide, contraceptives, excipient development, and topical pharmaceutical products. Evaluation of vaginal irritation is important to minimize chemical hazards to millions of women. The proposed human reconstructed tissue based system will provide a sensitive and validated assay method for screening of chemicals/formulations with vaginal irritation potential. Furthermore, the assay method will be cost effective and reduce the use of laboratory animals for experimentation.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government